ImmunityBio wins UAE marketing authorization for ANKTIVA in BCG-unresponsive bladder cancer

PUBT · 1d ago
ImmunityBio wins UAE marketing authorization for ANKTIVA in BCG-unresponsive bladder cancer
  • UAE drug regulator granted marketing authorization for ANKTIVA in BCG-unresponsive non-muscle invasive bladder cancer, covering CIS and papillary-only disease.
  • The clearance also covers metastatic non-small cell lung cancer in combination with immune checkpoint inhibitors for patients progressing on standard therapy.
  • The approvals were first registered on July 24, 2026, expanding ANKTIVA’s authorized footprint to 34 countries.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260729329364) on July 29, 2026, and is solely responsible for the information contained therein.